INNATE PHARMA SA (IPH.PA) Stock Earnings & Estimates
Europe - Euronext Paris - EPA:IPH - FR0010331421 - Common Stock
1.522 EUR
-0.04 (-2.56%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 49.58M 309.35% | 51.901M 4.68% | 12.622M -75.68% | 24.606M 94.95% | 35.409M 43.90% | 35.811M 1.14% | 64.861M 81.12% | 199.83M 208.09% | 255.4M 27.81% | 292.45M 14.51% | 307.72M 5.22% | |
| EBITDA YoY % growth | 28.98M 167.04% | -7.91M -127.29% | -50.01M -532.24% | -10.912M 78.18% | 71.305M 753.45% | 98.472M 38.10% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -16.425M 65.66% | -13M 20.85% | -52M -300.00% | -26.989M 48.10% | 22.38M 182.92% | -28.829M -228.82% | -65.419M -126.92% | 87.907M 234.38% | 138.63M 57.70% | 170.63M 23.08% | 180.29M 5.66% | |
| Operating Margin | -33.13% | -25.05% | -411.98% | -109.68% | 63.20% | -80.50% | -100.86% | 43.99% | 54.28% | 58.35% | 58.59% | |
| EPS YoY % growth | N/A 72.93% | N/A -169.82% | N/A 23.22% | -0.54 -32.84% | -0.50 8.46% | -0.45 9.31% | N/A | N/A | N/A | N/A | N/A |
All data in EUR
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.12 | -0.12 | -0.12 -9.09% | -0.07 72.00% | -0.13 -8.33% |
| Revenue Q2Q % growth | 1.98M | 2.172M -49.83% | 2.222M -54.35% | 7.817M 367.80% | 2.293M 15.81% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -12.857M | -12.665M 49.34% | -13.019M -34.83% | -8.211M 67.15% | -13.645M -6.13% |
All data in EUR
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2021 Q2Q % growth | -0.59 -629.56% | % | ||
| Q4 2020 Q2Q % growth | -0.08 | % | ||
| Q3 2020 Q2Q % growth | -0.08 | % | ||
| Q2 2019 Q2Q % growth | 0.20 | 0.32 | -0.12 | -38.12% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 1.671M -79.85% | 4.909M | -3.238M | -65.96% |
| Q4 2024 Q2Q % growth | 4.329M -73.85% | % | ||
| Q2 2024 Q2Q % growth | 8.293M -76.54% | % | ||
| Q4 2023 Q2Q % growth | 16.557M 99.27% | % | ||
| Q2 2023 Q2Q % growth | 35.344M -14.36% | % | ||
| Q4 2022 Q2Q % growth | 8.309M 118.20% | % | ||
| Q2 2022 Q2Q % growth | 41.271M 397.00% | % | ||
| Q4 2021 Q2Q % growth | 3.808M -85.53% | % | ||
| Q2 2021 Q2Q % growth | 8.304M -72.17% | % | ||
| Q4 2020 Q2Q % growth | 26.31M 51.33% | 27.379M | -1.069M | -3.90% |
| Q3 2020 Q2Q % growth | 22.86% | 27.379M | % | |
| Q2 2020 Q2Q % growth | 29.84M -42.16% | % | ||
| Q4 2019 Q2Q % growth | 17.386M | 22.285M | -4.899M | -21.98% |
| Q2 2019 Q2Q % growth | 51.588M | 58.735M | -7.147M | -12.17% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | N/A | 0% | -248.41% |
| Revenue | 0% | N/A | 0% | -72.88% |